Allele Biotechnology & Pharmaceuticals Closes Purchase of cGMP Facility for Production of Clinical-Grade Cells for Cell Therapy Applications

Allele to Generate Human Induced Pluripotent Stem Cells and Other Cell Types Under Cgmp

SAN DIEGO, June 9 (Bernama) -- Allele Biotechnology & Pharmaceuticals, Inc. ("Allele"), a leader in the development of specialized cells for pharmaceutical drug discovery and regenerative medicine, today announced that it has closed the purchase of a new facility intended for its cGMP (current good manufacturing practices) production of clinical-grade cells for cell therapy applications.

http://mrem.bernama.com/viewsm.php?idm=24627